News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
MarketBeat Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Summit Therapeutics Inc.'s average 12-month price target has been lowered to $28.34 from $29.52 by 14 analysts, yet this new target still suggests an 88% upside from its Aug. 11 closing price. The consensus rating for the stock remains a "Buy" among 18 analysts.
Summit Therapeutics (SMMT) shares rose after China's National Medical Products Administration approved a label expansion for its bispecific antibody ivonescimab, allowing its first-line use with chemotherapy for advanced squamous non-small cell lung cancer. Despite an extremely high price-to-sales ratio and ongoing losses, insider purchases …
Sharemaestro market context Trend signal active 52 weeks +87.0%[Approved red stamp sign.] * Shares of Summit Therapeutics (SMMT [https://seekingalpha.com/symbol/SMMT]) traded higher on Wednesday after the Chinese drug regulator, the National Medical Products Administration, approved a label expansion for the company’s lead drug, ivonescimab, developed with Akeso (AKESF [https://seekingalpha.com/symbol/AKESF]). * According to Summit …
Sharemaestro market context Price below Trend Line 52 weeks -31.8% · Next-week setup negative 7.4%Summit Therapeutics announced that its partner Akeso has received approval in China for ivonescimab for use in squamous non-small cell lung cancer (NSCLC). This approval marks a significant milestone for the bispecific antibody, which combines immunotherapy and anti-angiogenesis effects. Ivonescimab is also being developed …
Leerink Partners upgraded Summit Therapeutics (NASDAQ:SMMT) from "underperform" to "market perform" with a $13 price target. The company currently holds an average "Hold" rating from analysts with an average price target of $24.25, and recently reported quarterly EPS of -$0.28, missing estimates. Insider buying …
Summit Therapeutics (SMMT) has broadened its ivonescimab program by initiating a Phase II/III trial for first-line bladder cancer, adding to its growing list of target tumors. While this reinforces the long-term potential of ivonescimab, the near-term investment focus remains on the FDA's decision for …
Summit Therapeutics is expanding its ivonescimab development beyond lung cancer by initiating the HARMONi-GU1 Phase II/III trial for bladder cancer. This trial will test ivonescimab plus Astellas/Pfizer's Padcev against Merck's Keytruda plus enfortumab vedotin for first-line treatment of advanced urothelial carcinoma. The company aims …
Summit Therapeutics (SMMT) is currently assessed as 52% undervalued, with a fair value estimated at $28.36 against its closing price of $13.76. This valuation is largely based on ambitious assumptions regarding its ivonescimab program, which recently expanded with a new global Phase II/III bladder …
Sharemaestro market context Price below Trend Line 52 weeks -31.8% · Next-week setup negative 7.4%Summit Therapeutics has launched the HARMONi-GU1 trial, a global Phase II/III study evaluating ivonescimab in combination with an antibody-drug conjugate for bladder cancer. Ivonescimab is a bispecific antibody that blocks both PD-1 and VEGF pathways. This trial represents an expansion of Summit's HARMONi program, …
Summit Therapeutics (NASDAQ: SMMT) has initiated the global Phase II/III HARMONi-GU1 study for ivonescimab in urothelial carcinoma (bladder cancer). This randomized trial will evaluate ivonescimab plus enfortumab vedotin against pembrolizumab plus enfortumab vedotin as a first-line treatment for locally advanced or metastatic urothelial carcinoma, …
Summit Therapeutics has announced the expansion of its ivonescimab global development program with the initiation of the Phase II/III HARMONi-GU1 study for first-line bladder cancer. This trial will evaluate ivonescimab alongside enfortumab vedotin against the current standard of care, pembrolizumab plus enfortumab vedotin, in …
Summit Therapeutics Inc. (SMMT) presents a compelling opportunity in the biotechnology sector, with analysts projecting a potential upside of 117.69% based on an average target price of $28.34. The company, focused on innovative biopharmaceuticals like ivonescimab for cancer treatment, is currently in phase III …
Jim Cramer, host of "Mad Money," offered his insights on several stocks during a Lightning Round segment. He specifically highlighted
This article provides a comprehensive stock analysis of Summit Therapeutics Inc (SMMT) from TradingKey. It highlights the company's healthy fundamentals, high growth potential, and fairly valued stock, despite recent weak market performance. The analysis also details analyst ratings, institutional ownership, and key strengths like …
Summit Therapeutics has been upgraded from Sell to Hold due to the FDA's ongoing review of ivonescimab, with a decision anticipated by November 14, 2026. While the HARMONI study showed statistically significant progression-free survival, overall survival only presented a favorable trend. The company faces …
Summit Therapeutics (SMMT) recently announced a reduced net loss, a US$380 million equity offering, and updated overall survival data from its HARMONi trial for ivonescimab, alongside a new kidney cancer trial collaboration. The updated HARMONi data and expanded clinical focus reinforce ivonescimab's central role …
Sharemaestro market context Price below Trend Line 52 weeks -31.8% · Next-week setup negative 7.4%Summit Therapeutics Inc (SMMT) has an institutional shareholding score of 3.00, placing it 192nd out of 385 in the Biotechnology & Medical Research industry. The institutional shareholding proportion has increased by 11.68% quarter-over-quarter, now standing at 15.81%. Steven Cohen is the largest institutional shareholder, …
Summit Therapeutics announced its Q2 2026 financial results and significant clinical advancements for ivonescimab. Key highlights include consistent overall survival in both Western and Asian patients for EGFRm NSCLC post-TKI, and a statistically significant overall survival benefit for ivonescimab plus chemotherapy in 1L Squamous …
Summit Therapeutics (SMMT) stock has dropped to a 52-week low of $12.52, down nearly 60% from its high, with analysts revising earnings estimates downward. Despite this, InvestingPro suggests the stock may be undervalued. The company recently reported a Q2 net loss of $216 million, …
Kuehn Law, PLLC is investigating potential breaches of fiduciary duties by officers and directors of Summit Therapeutics Inc. (NASDAQ: SMMT) related to alleged self-dealing. The firm is encouraging long-term SMMT stockholders to contact them for a free consultation as they may be entitled to …
Kuehn Law, PLLC is investigating officers and directors of Summit Therapeutics Inc. for potential breaches of fiduciary duties and self-dealing, which could lead to shareholder damages and corporate governance reforms. Long-term shareholders are encouraged to seek a free consultation to explore their rights. This …
Summit Therapeutics (SMMT) has presented updated Phase III data for ivonescimab, a new PDUFA date, and a collaboration with Arcus Biosciences, yet its share price has declined in the short term. While a popular narrative suggests the company is 52% undervalued based on future …
Summit Therapeutics (SMMT) reported a Q4 2025 non-GAAP EPS miss, highlighting its status as a pre-revenue clinical-stage biotechnology firm with substantial cash burn. Despite the miss, the FDA's acceptance of the Biologics License Application (BLA) for ivonescimab in NSCLC, with a PDUFA date of …
Jefferies has lowered its price target for Summit Therapeutics (SMMT) shares to $15 from a previous $17, while reiterating a Hold rating on the stock. This adjustment reflects an updated valuation by the analyst firm, indicating a revised outlook for the company's future performance …
Summit Therapeutics Inc.'s average 12-month stock price target has been adjusted to $29.06, down from $29.84, based on estimates from 14 analysts. This new target suggests a potential upside of approximately 94% from its closing price on July 23. The consensus rating for SMMT …
Summit Therapeutics reported its Q2 2026 financial results, including a GAAP net loss of $215.7 million and non-GAAP net loss of $147.0 million. The company holds $690.7 million in cash and short-term investments and is actively advancing its lead asset, ivonescimab, a bispecific antibody …
Search by ticker symbol or company name and select a result to open its chart.